TOP STORY | Gene-Therapy Successes Spur Hope for Embattled Field Two studies show that 13 of 16 children treated with gene therapy for severe combined immune deficiency have had their immune systems restored, and one is in remission for leukemia that developed due to the gene therapy treatment. [Press release from NatureNews discussing online prepublications in Science Translational Medicine]
| SCIENCE NEWS | Study Sheds Light on Stem Cell Role in Regenerating Fingers, Toes Tissue-specific adult stem cells are responsible for the ability of mammals to re-grow the tips of fingers or toes lost to trauma or surgery, say researchers. [Press release from Stanford University School of Medicine discussing online prepublication in Nature]
Synthetic Self-Assembling Collagen for Tissue Engineering A team has tailored chains of amino acids so that they assemble themselves first into nanoscale fibrils, then entangle into larger fibers which in turn trap water to form a hydrogel – which mirrors the sequence of self-organization undertaken by natural collagen. [Press release from the Royal Society of Chemistry discussing online prepublication in Nature Chemistry]
Mural Cells from Saphenous Vein Could Have Long-Term Benefits in Heart Attacks New research has found the transplantation of stem cells that reside in human veins can help in the recovery of a heart attack. [Press release from the University of Bristol discussing online prepublication in Circulation Research]
Cardiac Researchers Discover Predictor of Stem Cell Efficacy in Treating Heart Failure Stem cell researchers discovered a factor that can serve as a predictor of stem cell development into blood vessels. [Press release from the University of Miami Miller School of Medicine discussing online prepublication in PLoS One]
Study Will Aid Parkinson’s Research Scientists have for the first time generated stem cells from one of the most rapidly progressing forms of Parkinson’s disease. [Press release from the University of Edinburgh discussing online prepublication in Nature Communications]
Controlling Cells’ Environments: A Step Toward Building Much-Needed Tissues and Organs With stem cells so fickle and indecisive that they make Shakespeare’s Hamlet pale by comparison, scientists described an advance in encouraging stem cells to make decisions about their fate. [Press release from the American Chemical Society discussing research presented at the 242nd National Meeting & Exposition for the American Chemical Society, Denver] Hair Cell-Derived Patient-Specific Heart Cells for Disease Modeling and Drug Screening Hair follicle keratinocytes offer a simple and accessible route to generate patient-specific induced pluripotent stem cells with minimum inconvenience for the patients, shows study. [Press release from the European Society of Cardiology (ESC) discussing research presented at the ESC Congress 2011, Paris]
| POLICY | Government of Canada Puts Patients First with New Research Strategy The Honorable Leona Aglukkaq, Minister of Health announced Canada’s Strategy for Patient-Oriented Research, a transformative research initiative that places patients at the centre of health care. [Canadian Institutes of Health Research, Canada] HHS Tightens Financial Conflict of Interest Rules for Researchers The U.S. Department of Health and Human Services (HHS) issued an updated Final Rule on conflict of interest, providing a framework for identifying, managing, and ultimately avoiding investigators’ financial conflicts of interest. [U.S. Department of Health and Human Services, United States] Cutting Back in Academia Upon the request of Congress, a US National Academy of Sciences panel is drafting a plan to help state universities deal with continuing budget cuts. [US National Academy of Sciences, United States]
Texas Med Board to Restrict Stem Cell Use The Texas Medical Board is seeking to put restrictions on stem cell transplants, a board member says. [Texas Medical Board, United States]
Scientists Promised ‘One Voice’ in European Policy A new Brussels-based group, ScienceEurope, is now positioning itself as the scientists’ champion in the fight to sway decision-makers. [ScienceEurope, Belgium]
| BUSINESS | Cleveland Researchers Collaborate to Launch Phase I Clinical Trial for New Multiple Sclerosis Treatment A team of researchers at three landmark Cleveland institutions have come together to launch a new clinical trial of an experimental treatment for multiple sclerosis. [Cleveland Clinic Press Release]
Grabel Receives New Human Stem Cell Research Grant Professor Laura Grabel has received a $750,000 grant for from The State of Connecticut Stem Cell Research Advisory Committee for her study titled “Angiogenesis of Embryonic Stem Cell Derived Hippocampus Transplants.” [Wesleyan University Press Release]
UC Davis Awarded Five Therapy Development Stem Cell Grants The California Institute for Regenerative Medicine approved research planning grants for five University of California, Davis (UC Davis) Health System teams that are working to develop human clinical trials to treat illnesses such as Huntington’s disease, vascular disease, osteoporosis, HIV/AIDS and airway disease in children. [University of California, Davis School of Medicine Press Release]
apceth Starts First Phase I/II Clinical Study on Somatic Cell Therapy for Peripheral Arterial Occlusive Disease apceth started its first Phase I/II clinical study on somatic cell therapy for advanced peripheral arterial occlusive disease after angioplasty. [B3C Newswire] Top-Line Results from Pivotal Trial of Dermagraft® for Venous Leg Ulcers Shire plc announced that Advanced BioHealing has concluded its Phase III pivotal trial of Dermagraft® in subjects with venous leg ulcers. Following preliminary analysis of the top-line results, the decision has been made not to pursue the venous leg ulcer indication. [Shire plc Press Release] Tekmira Acquires Worldwide Exclusive License to Novel RNAi Platform Tekmira Pharmaceuticals Corporation announced that it has obtained an exclusive, worldwide license to a novel and proprietary RNAi technology called MV-RNA (multivalent RNA) from Halo-Bio RNAi Therapeutics, Inc. [Tekmira Pharmaceuticals Corporation Press Release] Pluristem’s PLX Cells Receive Orphan Drug Status for Treatment of Buerger’s Disease Pluristem Therapeutics, Inc. announced that on August 22, 2011 the U.S. Food and Drug Administration designated Pluristem’s PLX cells orphan status for the treatment of thromboangiitis obliterans (Buerger’s disease). [Pluristem Therapeutics, Inc. Press Release] | |
|
|